CD37

CD37

a type III transmembrane protein present on mature B cells, some T cells, and monocytes that may play a role in ion transport; expressed on B-cell lymphomas, B-cell chronic lymphocytic leukemia, and hairy cell leukemia.
References in periodicals archive ?
CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52u CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279
Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.
Gene expression of T-cell markers such as CD3 a subunit of the T-cell receptor, was decreased in spleen, whereas in blood, HCB decreased gene expression for CD3 and CD37, the latter being a B-cell marker.
NYSE: EBS) today announced that the European Commission granted orphan medicinal product designation to Emergent's humanized single chain monoclonal antibody against CD37, also called TRU-016, for the treatment of chronic lymphocytic leukemia (CLL).
ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target.
Additionally, Abbott is evaluating a number of other promising mechanisms, including work on EGFR, CD37, aurora kinase and cMET, among others.
Additionally, Abbott is evaluating a number of other promising mechanisms, including work on EFGR, CD37, aurora kinase and cMET, among others.
Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of NHL and CLL.
ORAL PRESENTATION: Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals Publication #622 Monday, December 12, 2011, 3:30 PM
Among the data reported were that CD37 expression is comparable to that of CD20 on key NHL subtypes and CLL; that in preclinical testing the antibody component of IMGN529 demonstrates anticancer activity comparable to or greater than that of Rituxan[R] (rituximab); and that the complete IMGN529 TAP compound - antibody with attached DM1 cell-killing agent - demonstrates significantly greater anticancer activity than rituximab in preclinical models.
CD37 met these criteria; however, it was known to be difficult to develop humanized antibodies to this target that also have potent anticancer activity.
Of the therapeutics currently in development, targeting CD37 with TRU-016 appears to be among the most promising.